MMAPPP Act of 2020
Latest action · Jun 22, 2020 Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Science, Space, and Technology, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJun 22, 2020
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Make Medications Affordable by Preventing Pandemic Price gouging Act of 2020 or the MMAPPP Act of 2020
This bill imposes licensing and price restrictions on federally supported drugs and other medicines intended to address COVID-19 (i.e., coronavirus disease 2019) or other public health emergencies.
With respect to a COVID-19 drug patent developed using certain types of federal support, any license granted by the federal government shall be open and nonexclusive. Similarly, a licensee or assignee for such a patent shall grant open nonexclusive licenses for the patent. An entity that receives a license shall pay reasonable royalties to (1) the patent holder, or (2) the owner of marketing exclusivity rights granted by the Food and Drug Administration (FDA) that were terminated under this bill.
The bill requires that such drugs be offered at a fair and reasonable price based on certain considerations, such as access.
If the Department of Health and Human Services (HHS) finds that the price of any drug to address a public health emergency is excessive, HHS must void any FDA-granted exclusivity for the drug and grant open and nonexclusive licenses to other manufacturers. Such licenses are subject to reasonable royalty requirements.
Cosponsors 34
Members who signed on, in the order they did. Signatures ran from Jun 22, 2020 to Dec 2, 2020, with 6 there on the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-FL | Francis Rooney | Original | Jun 22, 2020 |
| D-TX | Lloyd Doggett | Original | Jun 22, 2020 |
| D-WI | Mark Pocan | Original | Jun 22, 2020 |
| D-OR | Peter A. DeFazio | Original | Jun 22, 2020 |
| D-WA | Pramila Jayapal | Original | Jun 22, 2020 |
| D-CT | Rosa L. DeLauro | Original | Jun 22, 2020 |
| D-NY | Nydia M. Velázquez | Jun 24, 2020 | |
| D-GA | Sanford D. Bishop, Jr. | Jun 26, 2020 | |
| D-IN | André Carson | Jul 6, 2020 | |
| D-MN | Betty McCollum | Jul 6, 2020 | |
| D-ME | Chellie Pingree | Jul 6, 2020 | |
| D-DC | Eleanor Holmes Norton | Jul 6, 2020 | |
| D-CT | Jahana Hayes | Jul 6, 2020 | |
| D-MD | Jamie Raskin | Jul 6, 2020 | |
| D-CA | Jared Huffman | Jul 6, 2020 |
Actions 2
Everything that happened, newest first.
- Jun 22, 2020Introduced in House
- Jun 22, 2020Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Science, Space, and Technology, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 4439 | MMAPPP Act of 2020 | Related bill | Aug 5, 2020 |
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Business records
- Cardiovascular and respiratory health
- Civil actions and liability
- Corporate finance and management
- Drug safety, medical device, and laboratory regulation
- Emergency medical services and trauma care
- Government information and archives
- Health
- Health programs administration and funding
- Health promotion and preventive care
- Immunology and vaccination
- Infectious and parasitic diseases
- Inflation and prices
- Intellectual property
- Licensing and registrations
- Manufacturing
- Medical research
- Medical tests and diagnostic methods
- Performance measurement
- Prescription drugs
- Research administration and funding
- Research and development
- User charges and fees
- Wages and earnings
Text 1
Each version as it was printed, newest first.
- Jun 22, 2020Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov.